Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Edge-to-Edge Repair in Cardiogenic Shock

The edge-to-edge approach with MitraClip has been established as a valid strategy for patients who experience severe symptomatic mitral regurgitation (MI) with high risk for surgery, currently with a IIa indication.

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

MI complicated by cardiogenic shock, which results in a high risk for conventional valve surgery, is a particularly complex scenario. In such a case, edge-to-edge repair emerges as an alternative, despite the current lack of exhaustive analyses or randomized studies, with only a handful of publications available.

Researchers conducted a meta-analysis that included 12 studies (7 case series and 5 observational studies) involving 460 patients.

The primary endpoint (PEP) assessed was mortality at one year.

Mean patient age was 68 years; 40% of patients were women. In general, 70% of patients had hypertension, 35% had diabetes, 43% had impaired renal function, 20% had chronic obstructive pulmonary disease (COPD), 11% had a prior stroke, 61% experienced coronary artery disease, and 49% had undergone a prior PCI. Additionally, 21% had undergone previous myocardial revascularization surgery. Ejection fraction was 36%.

Read also: Recurrent Revascularization at 10 Years after Percutaneous Treatment of DES In-Stent Restenosis.

About 74% of patients received inotropics, and a ventricular assist device was used as follows: 28% of patients received an intra-aortic balloon pump (IABP), 29% received an Impella device, and 13% of patients had extracorporeal membrane oxygenation (ECMO).

The most frequent cause of MI was functional (54%), followed by 26% of ischemic origin and 40% resulting from acute myocardial infarction (AMI).

The STS risk index was 17.7%.

The PEP at one year was 36% (95% confidence interval [CI]: 21%–54%), and the presence of MI <2+ was 88% (95% CI: 87%–89%).

Read also: Should We Use Ultrasound Routinely to Guide Transfemoral Access?

Mortality at 30 days was 11% (95% CI: 10%–13%) and 15% at 15 days (95% CI: 13%–16%), with an average hospital stay of 13.9 days (95% CI: 7.08–20.7).

Conclusion

This study is a systematic review and meta-analysis of the clinical features and evolution of edge-to-edge repair in cardiogenic shock in patients with mitral regurgitation. The edge-to-edge approach in mitral regurgitation with cardiogenic shock has been shown to be successful in reducing mitral regurgitation in most patients, although it is associated with a high mortality rate. Randomized controlled studies on edge-to-edge treatment of mitral regurgitation in cardiogenic shock are absolutely imperative.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Mmember of the Editorial Board of SOLACI.org.

Original Title: Transcatheter edge‐to‐edge mitral valve repair for mitral regurgitation in patients with cardiogenic shock: A systematic review and meta‐analysis.

Reference: Tetsuya Saito, et al. Catheter Cardiovasc Interv. 2024;103:340–347.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...